MediQ Star Secures Series A Investment from HB Investment

Funding Rounds

▤ Summary

MediQ Star closed a Series A round led by HB Investment to accelerate its AI healthcare technology and global expansion. Its core product, MycoScan, uses proprietary AI optics to rapidly diagnose tuberculosis and perform resistance testing faster and more simply than traditional liquid culture methods. The company plans to target high-burden regions in Southeast Asia, Latin America, and Africa, and to expand into AI CRO services and an AI diagnostic platform (MLLM) for diseases beyond TB, such as cervical cancer and pneumonia. HB Investment cited the solution’s potential to improve efficiency in resource-limited settings, and MediQ Star said the funds will speed up technical development and overseas market entry.

$ Funding

$
Amount None Total raised
□
Date July 4, 2025 Announcement date
◎
Investors - Lead investors
▥
Company - Funded company

▥ Classifications

industries
No industries detected
applications
No applications detected

◇ AskAI Classifications

Labels
No AI classifications detected

▦ Linked Companies